185 related articles for article (PubMed ID: 29336078)
1. The novel Axonics® rechargeable sacral neuromodulation system: Procedural and technical impressions from an initial North American experience.
Elterman DS
Neurourol Urodyn; 2018 Feb; 37(S2):S1-S8. PubMed ID: 29336078
[TBL] [Abstract][Full Text] [Related]
2. Programming settings and recharge interval in a prospective study of a rechargeable sacral neuromodulation system for the treatment of overactive bladder.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe M; Elneil S
Neurourol Urodyn; 2018 Feb; 37(S2):S17-S22. PubMed ID: 29336058
[TBL] [Abstract][Full Text] [Related]
3. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe M; Elneil S
Neurourol Urodyn; 2018 Feb; 37(S2):S9-S16. PubMed ID: 29315785
[TBL] [Abstract][Full Text] [Related]
4. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
[TBL] [Abstract][Full Text] [Related]
5. Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Perrouin-Verbe MA; Elneil S
Neurourol Urodyn; 2020 Apr; 39(4):1108-1114. PubMed ID: 32243625
[TBL] [Abstract][Full Text] [Related]
6. Sacral neuromodulation system for treating refractory overactive bladder.
Phillips A
Br J Nurs; 2020 Oct; 29(18):S30-S37. PubMed ID: 33035097
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the axonics modulation technologies sacral neuromodulation system for the treatment of urinary and fecal dysfunction.
Cohn JA; Kowalik CG; Kaufman MR; Reynolds WS; Milam DF; Dmochowski RR
Expert Rev Med Devices; 2017 Jan; 14(1):3-14. PubMed ID: 27915486
[TBL] [Abstract][Full Text] [Related]
8. Two-year outcomes of the ARTISAN-SNM study for the treatment of urinary urgency incontinence using the Axonics rechargeable sacral neuromodulation system.
Pezzella A; McCrery R; Lane F; Benson K; Taylor C; Padron O; Blok B; de Wachter S; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman HB
Neurourol Urodyn; 2021 Feb; 40(2):714-721. PubMed ID: 33508155
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-Month Results of the ARTISAN-SNM Study.
McCrery R; Lane F; Benson K; Taylor C; Padron O; Blok B; De Wachter S; Pezzella A; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; Le Normand L; Van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman HB
J Urol; 2020 Jan; 203(1):185-192. PubMed ID: 31347955
[TBL] [Abstract][Full Text] [Related]
10. Axonics Sacral Neuromodulation System for Treating Refractory Overactive Bladder: A NICE Medical Technologies Guidance.
Poole RL; Dale M; Morgan H; Oladapo T; Brookfield R; Morris R
Appl Health Econ Health Policy; 2022 May; 20(3):305-313. PubMed ID: 34964090
[TBL] [Abstract][Full Text] [Related]
11. Axonics® system for treatment of overactive bladder syndrome and urinary urgency incontinence.
Wang A; Rourke E; Sebesta E; Dmochowski R
Expert Rev Med Devices; 2021 Aug; 18(8):727-732. PubMed ID: 34187274
[No Abstract] [Full Text] [Related]
12. Review of the rechargeable sacral neuromodulation system to treat refractory overactive bladder.
Albabtain M; Chughtai B; Cho A; Elterman D
Ther Deliv; 2021 May; 12(5):353-362. PubMed ID: 33821666
[TBL] [Abstract][Full Text] [Related]
13. One-year outcomes of the ARTISAN-SNM study with the Axonics System for the treatment of urinary urgency incontinence.
Benson K; McCrery R; Taylor C; Padron O; Blok B; de Wachter S; Pezzella A; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; Van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman H; Lane F
Neurourol Urodyn; 2020 Jun; 39(5):1482-1488. PubMed ID: 32339339
[TBL] [Abstract][Full Text] [Related]
14. Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome.
Noblett KL; Dmochowski RR; Vasavada SP; Garner AM; Liu S; Pietzsch JB
Neurourol Urodyn; 2017 Mar; 36(3):727-733. PubMed ID: 27062384
[TBL] [Abstract][Full Text] [Related]
15. Initial experience using the Axonics sacral neuromodulation system in patients with multiple sclerosis.
Chen A; Kapur A; Mossack S; Weissbart SJ; Kim JM
Neurourol Urodyn; 2022 Aug; 41(6):1373-1379. PubMed ID: 35579263
[TBL] [Abstract][Full Text] [Related]
16. Satisfaction with a rechargeable sacral neuromodulation system-A secondary analysis of the ARTISAN-SNM study.
Geynisman-Tan J; Mueller MG; Kenton KS
Neurourol Urodyn; 2021 Jan; 40(1):549-554. PubMed ID: 33326643
[TBL] [Abstract][Full Text] [Related]
17. Sacral neuromodulation for lower urinary tract dysfunction.
Van Kerrebroeck PE; Marcelissen TA
World J Urol; 2012 Aug; 30(4):445-50. PubMed ID: 21989816
[TBL] [Abstract][Full Text] [Related]
18. Sacral neuromodulation: Rechargeable versus non-rechargeable device. What would the patient preferences be in France?
Gamé X; Ruffion A; Cornu JN; Phé V; Peyronnet B; Perrouin-Verbe MA; Aublant C; Adé A; Chartier-Kastler E
Prog Urol; 2022 Sep; 32(10):672-680. PubMed ID: 35752523
[TBL] [Abstract][Full Text] [Related]
19. [Results of sacral nerve modulation for treatment of overactive bladder].
Braun PM; Böhler G
Urologe A; 2006 Jul; 45(7):835-40. PubMed ID: 16773383
[TBL] [Abstract][Full Text] [Related]
20. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
